PEG-adenosine deaminase and PEG-asparaginase

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 51-58

  Davis, Frank F ^a  

^a Biotechnology Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; PEGADEMASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANAPHYLAXIS; CANCER REGRESSION; COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; CROSS LINKING; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADENOSINE DEAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CLINICAL TRIALS; EXCIPIENTS; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 0037957209     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (27)

1. Abuchowski, A., van Es, T., Palczuk, N.C., and Davis,F.F., 1977, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252: 3578-3581.
2. Abuchowski, A., McCoy, J.R., Palczuk, N.C., and Davis, F.F., 1977, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252: 3582-3586.
3. Liu, K-J., and Parsons, J.L., 1969, Solution effects on the preferred conformation of poly(ethylene) glycols. Macromol. 2: 529-533.
4. Giblett, E.R., Anderson, J.E., Cohen, F., Pollara,B., and Meuwissen, H.J., 1972, Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067-1069.
5. Benveniste, P., and Cohen, A., 1995, p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad .Sci. USA 92: 8373-9377.
6. Davis,S., Abuchowski, A., Park, Y.A., and Davis,F.F., 1981, Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46: 649-652.
7. Abuchowski, A., Kazo, G.M. Verhoest, Jr., C.R., van Es, T., Kafkewitz, D., Nucci, M.L., Viau, A.T. and Davis, F.F., 1984, Cancer therapy with chemically modified enzymes. 1. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7: 175-186.
8. Hershfield, M., Buckley, R.H., Greenberg, M.L., Melton, A.L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M.L., Kobayashi, R.H., Kobayashi, A.L., Abuchowski, A., 1987, Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Eng. J. Med., 310: 589-586.
9. Aiuti, A. Slavin, S. Aker, M. Ficara, S., et al., 2001, Correction of ADA-SCID defect without PEG-ADA therapy by stem/progenitor cell gene therapy combined with non-myeloablative conditioning. Blood 98: 780a.
10. Hershfield, M., 1997, Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In Poly(ethyleneglycol) Chemistry and Biological Applications(J. M. Harris and S. Zalipsky, eds.), ACS symposium series, 145-154.
11. Hirschhorn, R., 1993, Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediat. Res. 33: Suppl., S35-41.
12. Broome J.D. 1961, Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature, 191: 1114-1115.
13. Kidd, J.G. 1953 Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med. 98: 565-582.
14. Campbell, H.A., Mashburn, L.T., Boyse, E.A., and Old, L.J., 1967, Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. Biochem. 6: 721-729.
15. Kurtzberg, J., 2,000, Asparaginase. In Holland-Frei Cancer Medicine e. 5(R. C. Bast, Jr., et al., eds.) B.C. Decker, Inc., Hamilton, Ontario, Canada, pp. 699-705.
16. Abuchowski, A., Kazo, G., Verhoest, Jr., C.R., van Es, T., Kafkewitz. D., Nucci, M.L., Viau, A.T., and Davis, F.F. 1984, Cancer therapy with chemically modified enzymes.I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7: 175-186.
17. Ho, D.H., Brown, N.S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R.A., and Krakoff, I.H., 1986, Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab. Dispos. 14: 349-352.
18. Ho, D.S.W., Wang, C., Lin, J.R., Brown, N., Newman, R.A., Krakoff, I.H., 1988, Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits. Drug Metab. Dispos. 16: 27-29.
19. MacEwen, E.G., Rosenthal, R., Matus, R., Viau, A.T., Abuchowski, A., A preliminary study on the evaluation of asparaginase. Cancer 59: 2011-2015.
20. Abshire, T.C., et al., Weekly polyethylene glycol conjugated (PEG) L-asparaginase ASP) produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia (rALL): a pediatric oncology group (POG) study 9310. Proc. AM. Soc. Clin. Oncol. 14: 344.
21. Ettinger, L.J., Kurtzberg, J., Voute, P.A., Jurgens, H., Halpern, S.L., 1995, an open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75: 1176-1181.
22. Muss, H.B., Spell, N., Scudiery, D., Capizzi, R.L, Cooper, M.R., Cruz, J., Jackson, D.V., Richards, F., Spurr, C.L., White, R., Zekan, P.J., Franklin, A.J., 1990. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodkin's lymphoma. Invest.New Drugs 8: 125-130.
23. Muller, H-J., Loning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Schutz, V.V., Henze, G., Palma., J.C., Ritter, J., Pinhiero, J.P.V., Winkelhorst., M., Boos, J., 2,000, Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol. 110: 379-384.
24. Pinheiro, J.P.V., Muller, H.J., Schwabe, D., Gunkel, M., Palma, J.C., Henze, G., Shutz, V.V., Winkelhorst, M., Wurthwein, G., Boos, J., 2,001, Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukemia. Br. J. Haematol. 113: 115-119.
25. Silverman, L.B., et al., 2,001, Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 97: 1211-1218.
26. Fu, C.H., Martin-Aragon,S. Weinberg, K.I., et al., 2,001, Reversal of cytosine arabinoside (ARA-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Cancer Chemother.Pharmacol. 48: 123-133.
27. Taylor, C.W., Dorr, R.T., Fanta, P., et al., 2001, A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 47: 83-88.